Investigators at an academic medical center are designing a randomized, double-blind, placebo-controlled trial to evaluate a novel Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe plaque psoriasis. The primary endpoint is the absolute change in the Psoriasis Area and Severity Index (PASI) score from baseline to 16 weeks. Preliminary power calculations indicate that the current study design only yields 65% statistical power (), which is below the conventional 80% threshold. The research team meets to discuss protocol revisions to improve the study's ability to detect a true difference between the treatment and placebo groups.
Which of the following modifications would increase the statistical power of this trial? (Select all that apply)
- Expanding the target patient enrollment from 250 to 500 individualsAnswer
- Utilizing highly precise digital planimetry rather than subjective physician visual estimates to assess skin lesionsAnswer
- CChanging the acceptable probability of a Type I error () from 0.05 to 0.01
- DRedesigning the trial to detect a smaller minimum clinically important difference between the two groups
- ESelecting a non-parametric statistical test instead of a parametric test to analyze the normally distributed primary outcome data